Clinical Trials Logo
  1. Home
  2. Pemphigus
  3. NCT00278642

Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders

Pemphigus Clinical Trial

Official title:
High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial

Clinical Trial Summary

Autoimmune Bullous Skin Disorders are believed to be due to immune cells, cells that normally protect the body and are now causing damage to the body. This study is designed to examine whether treating patients with high dose cyclophosphamide (a drug which reduces the function of the immune system) together with anti-thymocyte globulin (a protein that kills the immune cells that are thought to be causing your disease), followed by return of the previously collected special blood cells (stem cells) will result in improvement of this disease. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the intense chemotherapy is to destroy the cells in the immune system which may be causing this skin disease. The purpose of the stem cell infusion is to restore the body's blood production, which will be severely impaired by the high dose chemotherapy and anti-thymocyte globulin.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00278642
Study type Interventional
Source Northwestern University
Contact
Status Terminated
Phase Phase 1
Start date September 2002
Completion date September 2011
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05534776 - Validation of 5-Point Investigator Global Assessments for Pemphigus
Not yet recruiting NCT05898308 - Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus Phase 4
Terminated NCT01559155 - Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Active, not recruiting NCT01974518 - Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Phase 3
Recruiting NCT05284929 - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Completed NCT00283712 - Use of Infliximab for the Treatment of Pemphigus Vulgaris Phase 2
Not yet recruiting NCT06285435 - Coagulation Activation in Patients With Pemphigus
Not yet recruiting NCT06454357 - A Clinical Study of B007 in the Treatment of Pemphigus. Phase 2/Phase 3
Completed NCT01299857 - Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Phase 3
Completed NCT00960713 - The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders N/A
Completed NCT00213512 - Effect of Anti CD20 in Pemphigus Desease Phase 2/Phase 3
Active, not recruiting NCT04400994 - IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus Phase 2
Recruiting NCT02237313 - Identification of Vulnerability Factors in the Course of Pemphigus Patients N/A
Terminated NCT03075904 - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Phase 1/Phase 2
Terminated NCT03762265 - A Study of PRN1008 in Patients With Pemphigus Phase 3
Recruiting NCT02365675 - Wound Dressings for Pemphigus and Pemphigoid N/A
Recruiting NCT01338103 - Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex N/A
Active, not recruiting NCT00656656 - Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus Phase 2
Completed NCT00127764 - European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus Phase 2/Phase 3